Vebreltinib is indicated for adult patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) confirmed by testing to carry MET
exon 14 skipping mutation.
This mutation accounts for approximately 3%–4% of lung cancer cases and belongs to a relatively rare category of driver gene mutations.
